|
Next-generation sequencing ordering trends in the cancer trajectory. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Eisai (Inst); Helsinn Healthcare (Inst); HERON |
Speakers' Bureau - Depomed; Eisai; Teva |
Research Funding - AstraZeneca (Inst); Merck (Inst); XBiotech (Inst) |
Travel, Accommodations, Expenses - Eisai; Helsinn Healthcare; Teva |